U.S. senator is trying to lower prices for medicines that are discovered with taxpayer dollars, and his effort amounts to a new twist to unraveling a complicated controversy that has embroiled the U.S. Department of Defense, large drug makers, numerous lawmakers, and consumer groups.

Late last month, Angus King (I-Maine) successfully added an amendment to a Defense Department funding bill that consumer groups say would effectively allow an end run around drug makers that priced products — which were developed with taxpayer dollars — higher than what is charged in seven other countries. The trigger would be determined by median prices and per capita income compared with the U.S.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • I believe Shrek will go for the well known ” Reverse Prozac Defense”. His lawyer will argue that subtherapuetic levels of fluoxetine in Bro’s blood caused him to commit the alleged deeds.

  • Hmm – Sanofi ” not pursuing the project for a “commercial return.” May I observe that I have my doubts?
    One is reminded of the old saw ‘”We are a non-profit corporation. That wasn’t the plan … it’s just the way things turned out.”

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.